Shaperon and MMV join forces to advance game-changing, cost-effective nanobody treatments to prevent malaria
Shaperon, a South Korean biotechnology company, and Medicines for Malaria Venture (MMV), a Swiss-based product development partnership, are joining forces to discover and evaluate next-generation nanobody approaches to develop affordable, long-acting chemopreventive malaria therapies. The partnership aims to accelerate the development of next-generation, passive malaria immunization – an essential new tool that delivers target-specific antibodies […]
Goal.com -